"We believe Insight TNBCtype can further enable clinical trial testing and ultimately become the standard of care for TNBC patients bringing TNBC into the age of precision medicine.” - Eric Dahlhauser, Insight Genetics CEO https://t.co/5yJ7eGfOvZ
Thank you @SABCSSanAntonio for a wonderful conference highlighting some of the most important work in cancer diagnostics and treatment. Already looking forward to 2019! #SABCS18#breastcancer#bcsm#TNBC
Thanks Dr. Sharma from @KUMedCenter for explaining the longterm outcomes of #TNBC for adjuvant AC chemotherapy patients. #SABCS18#bcsm https://t.co/lWVLtBtNV3
The @TNBCFoundation hosted a meeting at the San Antonio Breast Cancer Symposium dedicated exclusively to TNBC. An update from the #SABCS is now available online for our TNBC community. Read more at: https://t.co/HB1XQ2qQf6
In many ways, #TNBC is the last frontier in breast cancer, as there are currently no targeted therapeutics available for this population. We’re working to change that with Insight TNBCtype™. https://t.co/IvF7sklhZA #targetedtherapy#precisionmedicine https://t.co/lWVLtBtNV3
@teamoncology about Insight TNBCtype - “The opportunity to improve the treatment and lives of TNBC patients with a diagnostic that is CLIA-validated and commercially positioned to support clinical trials is a major step forward.” #TNBC#cancerdiagnostics https://t.co/5yJ7eGfOvZ
We are dedicated to improving the lives of cancer patients through advanced molecular diagnostics that enable precision cancer care. We're ready for this year's #SABCS18! #precisionmedicine#bcsm#TNBC
Insight TNBCtype is a new test that categorizes triple negative breast cancer tumors into distinct molecular subtypes. #breastcancer#bcsm#TNBC https://t.co/IvF7sklhZA
Insight Genetic contributed to two posters at #SABCS18 that showcase findings from the use of Insight TNBCtype! Stop by poster session #4 on Friday! #TNBC#bcsm